Mineralys Therapeutics, Inc. (MLYS) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.15
+15% vs avg
5yr avg: 2.74
30Y Low1.3·High3.8
ROE
↑
-36.9%
↓+43% vs avg
5yr avg: -65.1%
30Y Low-82%·High-37%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MLYS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Mineralys Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $2.5B | $598M | $311M | — | — | — |
| Enterprise Value | $1.8B | $2.3B | $483M | $262M | — | — | — |
| P/E Ratio → | -13.15 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 3.15 | 3.80 | 3.12 | 1.29 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MLYS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
MLYS Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -36.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -36.9% | -36.9% | -82.2% | -76.1% | — | — | — |
| ROA | -35.6% | -35.6% | -77.7% | -39.3% | -47.5% | -307.8% | -230.6% |
| ROIC | -46.4% | -46.4% | -107.3% | -244.8% | — | — | — |
| ROCE | -40.7% | -40.7% | -89.0% | -48.7% | -56.0% | -1513.7% | — |
MLYS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $173M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.27 | -0.60 | -0.20 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -18.78 | -717.81 | -28.79 |
Net cash position: cash ($173M) exceeds total debt ($0)
MLYS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Mineralys Therapeutics, Inc.'s current ratio of 43.76x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 23.76x to 43.76x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 43.76 | 43.76 | 14.02 | 23.76 | 13.98 | 2.20 | 0.29 |
| Quick Ratio | 43.76 | 43.76 | 14.02 | 23.76 | 13.98 | 2.20 | 0.29 |
| Cash Ratio | 43.45 | 43.45 | 13.53 | 22.57 | 13.65 | 2.10 | 0.28 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
MLYS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Mineralys Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $68M | $49M | $36M | $5M | $5M | $5M |
Peer Comparison
Compare MLYS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MLYSYou | $2B | -13.2 | — | — | — | — | -36.9% | -46.4% | — |
 CORT | $6B | 63.6 | 117.5 | 39.5 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
 SPRB | $79M | -1.1 | — | — | — | — | -109.2% | — | — |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 MNKD | $1B | 178.0 | 29.3 | 80.3 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 ARDX | $2B | -27.3 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 XOMA | $493M | 28.5 | 37.8 | 171.8 | 94.3% | 21.8% | 38.2% | 7.4% | 9.2 |
 CHRS | $212M | 1.2 | — | — | -37.3% | -429.5% | 275.4% | — | — |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See MLYS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MLYS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MLYS vs CORT
Side-by-side business, growth, and profitability comparison vs Corcept Therapeutics Incorporated.
Start ComparisonMLYS — Frequently Asked Questions
Quick answers to the most common questions about buying MLYS stock.
What is Mineralys Therapeutics, Inc.'s P/E ratio?
Mineralys Therapeutics, Inc.'s current P/E ratio is -13.2x. This places it at the 50th percentile of its historical range.
What is Mineralys Therapeutics, Inc.'s ROE?
Mineralys Therapeutics, Inc.'s return on equity (ROE) is -36.9%. The historical average is -65.1%.
Is MLYS stock overvalued?
Based on historical data, Mineralys Therapeutics, Inc. is trading at a P/E of -13.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.